Aspire Biopharma Holdings Inc. reports net revenue of $1,941 for Q3 2025
Aspire Biopharma Holdings Inc. reported a net revenue of $1,941 for Q3 2025, marking an increase from zero revenue in the same period of 2024. The company, an early-stage biopharmaceutical and supplements firm, completed a reverse acquisition, identifying Aspire Biopharma, Inc. as the accounting acquirer. This led to non-competition and lock-up agreements with certain officers, directors, and stockholders. The company's quarterly report includes discussions on accounting standards and policies.
Aspire Biopharma Holdings Inc. reported net revenue of $1.9 thousand for the three months ended September 30, 2025, compared to zero net revenue for the same period in 2024. The company is an early-stage biopharmaceutical and supplements company. During the reported period, Aspire Biopharma Holdings Inc. completed a reverse acquisition, after which Aspire Biopharma, Inc. was identified as the accounting acquirer. The reverse acquisition resulted in non-competition and lock-up agreements with certain officers, directors, and stockholders. Further discussions of recently issued accounting standards and significant accounting policies are included in the company’s quarterly report. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aspire Biopharma Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-25-022595), on November 14, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here
